Press release
Chronic Pulmonary Hypertension Market Size in the 7MM was ~USD 28,290 million in 2023, estimates DelveInsight
The Chronic Pulmonary Hypertension Market is an evolving segment of the global healthcare landscape, driven by the increasing Chronic Pulmonary Hypertension prevalence of the disorder and the continuous development of innovative treatment options. The Chronic Pulmonary Hypertension market encompasses various therapeutic categories, including antipsychotics, adjunctive therapies, and emerging treatment modalities.
Discover Key Insights into the Chronic Pulmonary Hypertension Market with DelveInsight's In-Depth Report @ Chronic Pulmonary Hypertension Market Size [https://www.delveinsight.com/sample-request/chronic-pulmonary-hypertension-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Chronic Pulmonary Hypertension Market Report
* In November 2024:- Merck Sharp & Dohme LLC- A Phase 2a Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-5475 in Adults With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease. Researchers are looking for ways to treat pulmonary hypertension (PH) caused by chronic obstructive pulmonary disease (COPD). The goal of the study is to learn if people who take MK-5475 can walk farther in 6 minutes at Week 24 compared to people who take placebo.
* The total prevalent cases of Chronic Pulmonary Hypertension in the US are expected to increase with a significant CAGR by 2034, from around 17,910 thousand cases in 2023 in the US.
* Among the European countries, Germany (26%) had the highest prevalent population of Chronic Pulmonary Hypertension, followed by the UK in 2023. On the other hand, Spain had the least diagnosed prevalent population around 15% of Chronic Pulmonary Hypertension in the same year.
* However, the prevalent cases of Chronic Pulmonary Hypertension are expected to decrease in Germany and Japan attributed to decrease in country population and other factors.
* In Japan, among prevalent cases of Chronic Pulmonary Hypertension, most cases were of Group II Chronic Pulmonary Hypertension (~5,724 thousand) in 2023. While least were in Group I Chronic Pulmonary Hypertension around 54 thousand in the same year.
* The Chronic Pulmonary Hypertension prevalent cases were segmented based on age in four agegroups
* Assessments as per DelveInsight's analysts show that the majority of cases of Chronic Pulmonary Hypertension are occupied by females in comparison to males. There were approximately ~6,806 thousand male and ~11,104 thousand female cases of Chronic Pulmonary Hypertension in 2023 in the US.
* The leading Chronic Pulmonary Hypertension Companies such as Attgeno, Insmed Incorporated, Merck Sharp & Dohme Corp., United Therapeutics, Actelion, Bayer, Merck Sharp & Dohme LLC, Epix Pharmaceuticals, Inc., Dong-A PharmTech Co., Ltd., Janssen, LP, and others
* Promising Chronic Pulmonary Hypertension Therapies such as Supernitro, Treprostinil Palmitil Inhalation Powder, MK-5475, Remodulin, bosentan, Riociguat (Adempas, BAY63-2521), PRX-08066, Udenafil, Macitentan, and others.
Stay ahead in the Chronic Pulmonary Hypertension Therapeutics Market with DelveInsight's Strategic Report @ Chronic Pulmonary Hypertension Market Outlook [https://www.delveinsight.com/sample-request/chronic-pulmonary-hypertension-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Chronic Pulmonary Hypertension Epidemiology Segmentation in the 7MM
* Total Chronic Pulmonary Hypertension Prevalent Cases
* Chronic Pulmonary Hypertension Group-specific Prevalent Cases
* Chronic Pulmonary Hypertension Group-specific Prevalent Cases
* Chronic Pulmonary Hypertension Age-specific Prevalent Cases
Download the report to understand which factors are driving Chronic Pulmonary Hypertension epidemiology trends @ Chronic Pulmonary Hypertension Prevalence [https://www.delveinsight.com/sample-request/chronic-pulmonary-hypertension-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Chronic Pulmonary Hypertension Marketed Drugs
* ADEMPAS (riociguat): Bayer
ADEMPAS (riociguat) is indicated for the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class. Riociguat is a stimulator of soluble guanylate cyclase (sGC), an enzyme in the cardiopulmonary system and the receptor for nitric oxide (NO). Riociguat has a dual mode of action. It sensitizes sGC to endogenous NO by stabilizing the NO-sGC binding.
Chronic Pulmonary Hypertension Emerging Drugs
* CS1: Cereno Scientific AB
The drug candidate CS1 is a HDAC inhibitor with a new advanced reformulation of valproic acid (VPA) and acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic, and pressure-relieving properties. CS1 is being developed as a treatment for the rare disease PAH with the aim of offering patients a better and safer disease-modifying drug. CS1's unique efficacy profile fits well with the pathogenetic mechanisms of the rare disease PAH and is believed to be able to address today's major unmet need for better treatment alternatives.
Get In-Depth Knowledge on Chronic Pulmonary Hypertension Market Trends and Forecasts with DelveInsight @ Chronic Pulmonary Hypertension Treatment Market [https://www.delveinsight.com/sample-request/chronic-pulmonary-hypertension-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Chronic Pulmonary Hypertension Market Outlook
Phosphodiesterase-5 (PDE-5) inhibitors such as Sildenafil and Tadalafil are efficient in providing the antiproliferative effects on vascular smooth muscle cells and inducing vasodilation. Endothelin receptor antagonists such as Ambrisentan, Bosentan and Macitentan exertvasoconstrictor and mitogenic effects on the pulmonary vascular smooth muscles. Nifedipine, diltiazem, or amlodipine are the most commonly recommended calcium channel blockers being used for the treatment of Pulmonary Arterial Hypertension. Prostacyclins such as epoprostenol, treprostinil, iloprost are recommended for improving the functional capacity and survival rate among the patients of Pulmonary Hypertension. Apart from the aforesaid, IP prostacyclin receptor agonists are also used in the treatment of Chronic PH. They bind selectively to the IP receptor and follow the prostacyclin pathway.
Scope of the Chronic Pulmonary Hypertension Market Report
* Coverage- 7MM
* Chronic Pulmonary Hypertension Companies- Attgeno, Insmed Incorporated, Merck Sharp & Dohme Corp., United Therapeutics, Actelion, Bayer, Merck Sharp & Dohme LLC, Epix Pharmaceuticals, Inc., Dong-A PharmTech Co., Ltd., Janssen, LP, and others
* Chronic Pulmonary Hypertension Therapies- Supernitro, Treprostinil Palmitil Inhalation Powder, MK-5475, Remodulin, bosentan, Riociguat (Adempas, BAY63-2521), PRX-08066, Udenafil, Macitentan, and others.
* Chronic Pulmonary Hypertension Market Dynamics: Chronic Pulmonary Hypertension Market Drivers and Barriers
* Chronic Pulmonary Hypertension Market Access and Reimbursement, Unmet Needs and Future Perspectives
Unlock Strategic Insights with DelveInsight's Comprehensive Chronic Pulmonary Hypertension Market Report @ Chronic Pulmonary Hypertension Market Drivers and Barriers [https://www.delveinsight.com/sample-request/chronic-pulmonary-hypertension-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
1 Key Insights
2 Report Introduction
3 Chronic Pulmonary Hypertension Market Overview at a Glance
4 Epidemiology and Market Forecast Methodology of Chronic Pulmonary Hypertension
5 Executive Summary of Chronic Pulmonary Hypertension
6 Key Events
7 Disease Background and Overview
8 Epidemiology and Patient Population
9 Patient Journey
10 Marketed Drugs
11 Emerging Drugs
12 Chronic Pulmonary Hypertension: Seven Major Market Analysis
13 KOL Views
14 SWOT Analysis
15 Unmet Needs
16 Market Access and Reimbursement
17 Appendix
18 DelveInsight Capabilities
19 Disclaimer
20 About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: yash bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-pulmonary-hypertension-market-size-in-the-7mm-was-usd-28290-million-in-2023-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Pulmonary Hypertension Market Size in the 7MM was ~USD 28,290 million in 2023, estimates DelveInsight here
News-ID: 3733814 • Views: …
More Releases from ABNewswire
Stock Strategies and the Top 10 U.S. Stocks by Market Capitalization
Understanding the stock market requires not only tracking price movements but also knowing the best Stock Strategy [https://stockstrategy.net/] that guide profitable trading and investment decisions. In 2025, the U.S. stock market continues to be dominated by technology giants and innovative companies leading global economic growth. Below, we explore effective stock strategies and reveal the top 10 U.S. stocks by market capitalization for 2025.
What Are Stock Strategies?
Stock Strateg [https://stockstrategy.net/]ies are systematic…
Find the Best 5-Function Electric Hospital Bed Suppliers Powering the U.S. Healt …
Image: https://www.abnewswire.com/upload/2025/10/fc6a2d1f88f2a0f77734b0c452f09cb3.jpg
In modern healthcare, innovation and patient comfort go hand in hand. Hospitals, clinics, and care facilities across the United States are constantly searching for smarter, safer, and more comfortable medical furniture. Among these essential tools, electric hospital beds play a pivotal role in improving patient care and recovery. As the US electrical hospital beds market [https://www.gracemedy.com/top-10-hospital-bed-manufacturers-in-the-usa/] continues to expand rapidly, one name stands out among the top suppliers shaping…
How to Select and Build a Highly Successful Career: The Modern Blueprint for Pro …
In a world where industries evolve faster than ever, choosing and building a successful career has become one of life's most important decisions. Whether you're a student, a professional at a crossroads, or someone seeking deeper fulfillment beyond a paycheck, success today is about aligning passion, skill, and purpose - not just following trends.
This press release presents a modern blueprint on how to select and build a highly successful career,…
Sweet Trolley Targets Corporate Recognition Market with Subscription Candy Gifts …
Sweet Trolley has positioned its branded refillable candy jar service to serve corporate recognition programs, targeting HR and sales leaders seeking meaningful employee and client appreciation tools. The newly launched company offers corporate gift buyers scalable solutions combining nostalgic candy presentations with year-round refill subscriptions and custom label capabilities for branding integration.
Sweet Trolley has strategically positioned its refillable candy jar concept to serve the corporate employee recognition and client appreciation…
More Releases for Pulmonary
Innovation In Pulmonary Drug Delivery Devices Industry Trends Gaining Momentum i …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Pulmonary Drug Delivery Devices Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for pulmonary drug delivery devices has experienced significant growth in the past few years. The market is projected to increase from $49.52 billion in 2024 to $52.8 billion in 2025,…
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC…
New Study: Pulmonary Drugs Market Report
The pulmonary drugs market is expected to witness unprecedented growth in the near future, thanks to large number of approvals from the FDA. The FDA approved a large number of pulmonary drugs for major illnesses like small-cell lung cancer, tuberculosis, and pneumonia over the past few years. Additionally, newly approved drugs also treat newly found diseases like obstructive sleep apnea. These approvals are in line with the recent trend of…
Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs
Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated…
Pulmonary Drug Delivery Devices Market: Demand for Pulmonary Drug Delivery Devic …
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market.
This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments…
